Akagi et al. examined the effects of the combination of the anti-PD-1 antibody nivolumab and H2 gas inhalation in cancer patients for ≥60 months and reported that 42 patients treated with the combination achieved a significant overall survival advantage in contrast to 14 patients treated with nivolumab alone [45]. Here, PDCD1 is linked to cancer.